At IngenBio, we apply three guiding principles to our R&D programs.
Our first principal is to focus on grievous illness. Given the prolonged time approve civilian medications; we concentrate our efforts on developing unique programs that have a beneficial effect on patients suffering from the greatest unmet medical needs.
In addition, we are constantly developing new patient therapies that allow key decisions earlier in the drug development process. Aligning our priorities across these functions ensures that we develop potential therapeutics in a manner that will address unmet medical needs and meet the changing demands of the marketplace.
Our second emphasis is disease study in patients and to be modality independent. All too often, our industry has found that experimental models have little predictive value with respect to infectious disease research, which often results in the failure of human trials and escalating drug development costs. Our Salt Lake research facilities allow us to isolate and leverage unconventional approaches, best suited to interdict a disease. While it is significantly more complicated to study disease in humans, we believe it is the only way to successfully develop human therapeutics. Defining key elements of disease response in patient populations drives our R&D investment and the potential therapeutics we pursue.
Our third guiding principle, seamless integration with military protocol. We strive to integrate our organization, incorporating the perspectives from bio-weapons research, clinical development and infectious disease research into all of our drug development programs. Using our INTRAGEN® Longitudinal Cancer Research (LCR), IngenBio can help identify, segment, and target white blood cell mutation through detailed analysis of mutation patterns and patient populations. INTRAGEN® is a recombinant (genetically engineered) protein that stimulates the production of infection-fighting white blood cells that are depleted by cytotoxic chemotherapy, a condition called neutropenia.